Dynamic Advisor Solutions LLC Grows Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Dynamic Advisor Solutions LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 58.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,055 shares of the company’s stock after buying an additional 4,811 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in AstraZeneca were worth $960,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Cibc World Markets Corp raised its position in shares of AstraZeneca by 1.1% during the 4th quarter. Cibc World Markets Corp now owns 12,901 shares of the company’s stock valued at $845,000 after buying an additional 142 shares during the period. CoreCap Advisors LLC raised its position in shares of AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock valued at $42,000 after buying an additional 155 shares during the period. Tiller Private Wealth Inc. raised its position in shares of AstraZeneca by 5.7% during the 4th quarter. Tiller Private Wealth Inc. now owns 3,350 shares of the company’s stock valued at $219,000 after buying an additional 181 shares during the period. Dorsey & Whitney Trust CO LLC raised its position in shares of AstraZeneca by 0.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company’s stock valued at $2,313,000 after buying an additional 189 shares during the period. Finally, Pine Valley Investments Ltd Liability Co raised its position in shares of AstraZeneca by 3.3% during the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 5,995 shares of the company’s stock valued at $393,000 after buying an additional 190 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 3.5%

Shares of NASDAQ AZN opened at $70.97 on Wednesday. The firm has a market cap of $220.10 billion, a price-to-earnings ratio of 28.50, a PEG ratio of 1.35 and a beta of 0.38. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The business’s 50 day moving average is $70.07 and its two-hundred day moving average is $70.35.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.06 earnings per share. Research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

Analysts Set New Price Targets

Separately, BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $85.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.